Past Meetings

DAY 1:
Basic T Cell Biology and Function

 Friday, June 10th, 2016

Session 1: Basic T Cell Biology
Steve Hedrick, UCSD "CD8 T cell response to persistent viral infection" 1:00-1:40
David Masopust, U of Minnesota "Resident Memory T Cells: Quantity, Location, & Function" 1:40-2:20
Doug Green, St Judes, Memphis "Metabolic Maintenance of Asymmetric T cell Division" 2:20-3:00
Charlie Surh, Institute for Basic Science, Korea, "Cellular Mechanisms of Treg Suppression" 3:00-3:40

Session 2: T Cell Function in Tumor-Bearing Hosts
Steve Ziegler
, Benaroya Institute, Seattle "Immune regulation of tumor progression" 4:00-4:40
Thomas Duhen, AgonOx, Inc, "A Deeper Dive into Human CD4 Tumor Infiltrating Lymphocytes" 4:40-5:20
Pam Ohashi, U of Toronto, "Novel Subsets in T cell Anti-Tumor Immunity" 5:20-6:00
Lanny Kirsch - Immunosequencing in the Service of T-cell Diseases and T-cell Therapeutics" 6:00-6:40

DAY 2:
Preclinical Cancer Immunotherapy

Saturday, June 11th, 2016

Session 1: Tumor-Specific T Cell Response
Bob Schreiber, Washington University, St Louis "Personalizing Cancer Immunotherapy" 1:00-1:40
Brad Nelson, U of British Columbia, Victoria "How does the tumor genome shape the immune response to cancer?" 1:40-2:20
Andy Weinberg, Providence Cancer Center, Oregon" A Deeper Dive into Human CD4 and CD8 TIL Phenotype and Clonality" 2:20-3:00
Bernie Fox, Providence Cancer Center, Oregon "Impersonalization of Cancer: Development of a Universal Cancer Vaccine" 3:00-3:40

Session 2: Immune Therapeutic Pathways
Lieping Chen, Yale "PD-1H Pathway" 4:00-4:40
Carl Ware, Burnham Institute, San Diego "The LIGHT HVEM Network in anti Tumor Responses" 4:40-5:20
Samir Khleif, Georgia Reagents University "PI3K Pathway in T Cell Regulation" 5:20-6:00
Mark Smyth, QIMR Berghofer Medical Research Institute, "Superior Power of Neoadjuvant Immunotherapy to Eradicate Metastatic Disease" 6:00-6:40


DAY 3:
Clinical Immunotherapy

Sunday, June 12th, 2016

Session 1: Treating Cancer Patients with Immunotherapy
Mario Sznol, Yale "Clinical Development of Checkpoint Inhibitors in Melanoma" 
Edward Garon, UCLA "Checkpoint Intuition in Lung Cancer - Immunotherapy Meets the Masses" 
Rom Leidner, Providence Cancer Center "The Promise of Immunotherapy in Head and Neck Cancer" 
Carl June, U of Penn, Philadelphia "Adoptive T cell Therapy for Cancer" 

Session 2: Investigating Clinical Immunotherapy Samples
Brendan Curti, Providence Cancer Center, Oregon "Clinical Development of OX40 Agonists
Tom Gajewski, U of Chicago "T cell-inflamed tumor microenvironment and response to immunotherapy" 
Paul Tumeh, UCLA "Spatial Immune Profiling of the Cancer Microenvironment" 
Lisa Butterfield, University of Pittsburgh "T Cell responses to shared tumor antigens in cancer patients" 



T cell Function and Modulation Meeting

Maui (Makena, HI) April 28 - May 1, 2013

Makena Beach & Golf Resort

This meeting was held prior to the AAI 100th Anniversary Meeting in Honolulu, HI.

This conference brought together some of the most talented scientists involved with understanding T cell function and promoted discussions regarding using this information for therapeutic intervention. Understanding the principles of T cell function allows for the potential to manipulate the outcome of hosts with disease. 


Doug Green: St Jude's
Michael Croft: LIAI
Charles Surh: Institute for Basic Science (IBS; Korea)
Leo Lefrançois: Univ of Connecticut
Lynn Puddington: Univ of Connecticut
Andy Hurwitz: NCI
Protul Shrikant: Roswell Park
Carl Ware: Burnham Institute
Lieping Chen: Yale
Yang-Xin Fu: Univ of Chicago
Thomas Gajweski: Univ of Chicago
Steve Jameson: Univ of Minnesota
Andy Weinberg: Providence Cancer Center
Bernie Fox: Providence Cancer Center
Daniel Campbell: Univ of Washington
Stephen Hedrick: UCSD
Stephen Schoenberger: LIAI
Jeff Rathmell: Duke
Dario Vignali: St Jude's
Linda Sherman: Scripps
Pam Sharma: MD Anderson
Maria-Luisa Alegre: Univ of Chicago
James Allison:  MD Anderson
Andrew Pierce:  MedImmune